4 results on '"Keiko Ohta‐Ogo"'
Search Results
2. Different sizes of centrilobular ground-glass opacities in chest high-resolution computed tomography of patients with pulmonary veno-occlusive disease and patients with pulmonary capillary hemangiomatosis
- Author
-
Hiromi Matsubara, Kazufumi Nakamura, Hiroshi Ito, Katsushi Hashimoto, Aiji Ohtsuka, Tohru Ohe, Shinichi Toyooka, Kunihisa Kohno, Takahiro Oto, Aya Miura, Kengo Kusano, Satoshi Nagase, Keiko Ohta-Ogo, Satoshi Akagi, and Aiko Ogawa
- Subjects
Adult ,Male ,medicine.medical_specialty ,High-resolution computed tomography ,Lung Neoplasms ,Adolescent ,Hypertension, Pulmonary ,medicine.medical_treatment ,Autopsy ,Pulmonary capillary hemangiomatosis ,Pathology and Forensic Medicine ,Diagnosis, Differential ,Young Adult ,Imaging, Three-Dimensional ,Predictive Value of Tests ,medicine ,Humans ,Replica Techniques ,Lung transplantation ,Familial Primary Pulmonary Hypertension ,Hemangioma, Capillary ,Child ,Lung ,medicine.diagnostic_test ,business.industry ,General Medicine ,medicine.disease ,Pulmonary hypertension ,Capillaries ,Respiratory Function Tests ,medicine.anatomical_structure ,Pulmonary Veno-Occlusive Disease ,Radiographic Image Interpretation, Computer-Assisted ,Female ,Radiology ,Differential diagnosis ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business ,Lung Transplantation - Abstract
Centrilobular ground-glass opacity (GGO) is one of the characteristic findings in chest high-resolution computed tomography (HRCT) of patients with pulmonary veno-occlusive disease (PVOD) and patients with pulmonary capillary hemangiomatosis (PCH). However, clinical differential diagnosis of these two diseases is difficult and has not been established. In order to clarify their differences, we compared the sizes of GGOs in chest HRCT and the sizes of capillary assemblies in pulmonary vascular casts between patients diagnosed pathologically with PVOD and PCH.We evaluated chest HRCT images for four patients with idiopathic pulmonary arterial hypertension (IPAH), three patients with PVOD and three patients with PCH, and we evaluated pulmonary vascular casts of lung tissues obtained from those patients at lung transplantation or autopsy.Centrilobular GGOs in chest HRCT were observed in patients with PVOD and patients with PCH but not in patients with IPAH. We measured the longest diameter of the GGOs. The size of centrilobular GGOs was significantly larger in patients with PCH than in patients with PVOD (5.60±1.43 mm versus 2.51±0.79 mm, P.01). We succeeded in visualization of the 3-dimensional structures of pulmonary capillary vessels obtained from the same patients with PVOD and PCH undergoing lung transplantation or autopsy and measured the diameters of capillary assemblies. The longest diameter of capillary assemblies was also significantly larger in patients with PCH than in patients with PVOD (5.44±1.71 mm versus 3.07±1.07 mm, P.01).Measurement of the sizes of centrilobular GGOs in HRCT is a simple and useful method for clinical differential diagnosis of PVOD and PCH.
- Published
- 2013
3. Elevated oxidative stress is associated with ventricular fibrillation episodes in patients with Brugada-type electrocardiogram without SCN5A mutation
- Author
-
Takeshi Tada, Masato Murakami, Nobuhiro Nishii, Kazufumi Nakamura, Yoshiki Hata, Kunihisa Kohno, Keiko Ohta-Ogo, Koji Nakagawa, Masamichi Tanaka, Hiroshi Morita, Kengo Fukushima Kusano, Aya Miura, Mamoru Ouchida, Hiroshi Ito, Kenji Shimizu, Daiji Miura, Tohru Ohe, Chikao Yutani, and Satoshi Nagase
- Subjects
Male ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Antigens, Differentiation, Myelomonocytic ,Muscle Proteins ,medicine.disease_cause ,Sodium Channels ,NAV1.5 Voltage-Gated Sodium Channel ,Pathology and Forensic Medicine ,Electrocardiography ,Antigens, CD ,Internal medicine ,Humans ,Medicine ,cardiovascular diseases ,Brugada Syndrome ,DNA Primers ,Brugada syndrome ,Aldehydes ,Base Sequence ,medicine.diagnostic_test ,business.industry ,CD68 ,Myocardium ,Cardiac arrhythmia ,General Medicine ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Pathophysiology ,Oxidative Stress ,Mutation ,Ventricular Fibrillation ,Mutation (genetic algorithm) ,Ventricular fibrillation ,cardiovascular system ,Cardiology ,Leukocyte Common Antigens ,Female ,Lipid Peroxidation ,Cardiology and Cardiovascular Medicine ,business ,Oxidative stress ,Endocardium - Abstract
Brugada syndrome is a disease known to cause ventricular fibrillation with a structurally normal heart and is linked to SCN5A gene mutation. However, the mechanism by which ventricular fibrillation develops in cases of Brugada-type electrocardiogram without SCN5A mutation has remained unclear. Recently, oxidative stress has been implicated in the pathophysiology of cardiac arrhythmia. We also investigated oxidative stress levels in the myocardia of patients with Brugada-type electrocardiogram.Endomyocardial biopsy samples were obtained from 68 patients with Brugada-type electrocardiogram (66 males and two females). We performed histological and immunohistochemical analyses for CD45, CD68, and 4-hydroxy-2-nonenal-modified protein, which is a major lipid peroxidation product.SCN5A mutation was detected in 14 patients. Ventricular fibrillation was documented in three patients with SCN5A mutation and in 11 without SCN5A mutation. In patients with SCN5A mutation, 4-hydroxy-2-nonenal-modified protein-positive area was not significantly different between the documented ventricular fibrillation (VF) group (VF+ group) and the group without documented VF (VF- group). However, in patients without SCN5A, the area was significantly larger in the VF+ group than that in the VF- group (P.05). All other parameters (fibrosis area, CD45, and CD68) were not different between the VF+ and VF- group in both SCN5A+ and SCN5A- patients.Oxidative stress is elevated in the myocardium of patients with Brugada-type electrocardiogram who have VF episodes and do not have SCN5A gene mutations. Oxidative stress may be associated with the occurrence of VF in patients with Brugada-type electrocardiogram without SCN5A mutation.
- Published
- 2011
4. Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy
- Author
-
Tohru Ohe, Kengo Fukushima Kusano, Jun Iwasaki, Kimikazu Banba, Hiroshi Morita, Norihisa Toh, Keiko Ohta-Ogo, Takefumi Oka, Nobuhiro Nishii, Hiromi Matsubara, Hideo Kimura, Masato Murakami, Satoshi Nagase, Kazufumi Nakamura, and Yoichi Nakamura
- Subjects
Male ,Cardiac function curve ,medicine.medical_specialty ,medicine.medical_treatment ,Cardiomyopathy ,Enzyme-Linked Immunosorbent Assay ,Pathology and Forensic Medicine ,Muscle hypertrophy ,Pathogenesis ,Ventricular Dysfunction, Left ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,Chemokine CCL2 ,Cardiac catheterization ,business.industry ,Myocardium ,Monocyte ,Hypertrophic cardiomyopathy ,General Medicine ,Cardiomyopathy, Hypertrophic ,Middle Aged ,medicine.disease ,Immunohistochemistry ,medicine.anatomical_structure ,Heart failure ,Disease Progression ,cardiovascular system ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Progression of hypertrophic cardiomyopathy (HCM) to left ventricular dilatation and systolic dysfunction sometimes occurs. However, the mechanism of the transition from hypertrophy to dysfunction has not been elucidated. It has been reported that circulating levels of monocyte chemoattractant protein-1 (MCP-1), which is a major factor promoting the accumulation of macrophages, are increased in patients with congestive heart failure. We measured circulating levels of MCP-1 in patients with HCM and examined whether MCP-1 was expressed in the myocardium of HCM patients. We also examined whether circulating levels of MCP-1 were correlated with left ventricular dysfunction.Circulating levels of MCP-1 were measured by an enzyme immunoassay in 26 patients with HCM (60+/-2 years old) and 20 control subjects (57+/-2 years old). Cardiac function was evaluated by two-dimensional echocardiography and cardiac catheterization.HCM patients had significantly elevated levels of MCP-1 (HCM: 309+/-30 vs. control: 178+/-8 pg/ml, P.001). MCP-1 levels in patients with systolic dysfunction were significantly higher than those in patients without systolic dysfunction (P.05) and were also significantly higher than those in patients with outflow obstruction (P.05). Immunohistochemical analysis revealed that MCP-1 was expressed in endomyocardial biopsy samples obtained from HCM patients with systolic dysfunction. Furthermore, MCP-1 levels were inversely correlated with fractional shortening (r=-.401, P.05) and correlated with left ventricular end-diastolic pressure (r=-.579, P.01).These results show that MCP-1 is associated with, and might be involved in the pathogenesis of, left ventricular systolic dysfunction in patients with HCM.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.